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Summary
Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 
5 years substantially reduces the breast cancer mortality rate throughout the ﬁ rst 15 years after diagnosis. We aimed 
to assess the further eﬀ ects of continuing tamoxifen to 10 years instead of stopping at 5 years.
Methods In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12 894 women with early 
breast cancer who had completed 5 years of treatment with tamoxifen were randomly allocated to continue tamoxifen 
to 10 years or stop at 5 years (open control). Allocation (1:1) was by central computer, using minimisation. After entry 
(between 1996 and 2005), yearly follow-up forms recorded any recurrence, second cancer, hospital admission, or 
death. We report eﬀ ects on breast cancer outcomes among the 6846 women with ER-positive disease, and side-eﬀ ects 
among all women (with positive, negative, or unknown ER status). Long-term follow-up still continues. This study is 
registered, number ISRCTN19652633. 
Findings Among women with ER-positive disease, allocation to continue tamoxifen reduced the risk of breast cancer 
recurrence (617 recurrences in 3428 women allocated to continue vs 711 in 3418 controls, p=0·002), reduced breast 
cancer mortality (331 deaths vs 397 deaths, p=0·01), and reduced overall mortality (639 deaths vs 722 deaths, p=0·01). 
The reductions in adverse breast cancer outcomes appeared to be less extreme before than after year 10 (recurrence rate 
ratio [RR] 0·90 [95% CI 0·79–1·02] during years 5–9 and 0·75 [0·62–0·90] in later years; breast cancer mortality RR 0·97 
[0·79–1·18] during years 5–9 and 0·71 [0·58–0·88] in later years). The cumulative risk of recurrence during years 5–14 
was 21·4% for women allocated to continue versus 25·1% for controls; breast cancer mortality during years 5–14 was 
12·2% for women allocated to continue versus 15·0% for controls (absolute mortality reduction 2·8%). Treatment 
allocation seemed to have no eﬀ ect on breast cancer outcome among 1248 women with ER-negative disease, and an 
intermediate eﬀ ect among 4800 women with unknown ER status. Among all 12 894 women, mortality without 
recurrence from causes other than breast cancer was little aﬀ ected (691 deaths without recurrence in 6454 women 
allocated to continue versus 679 deaths in 6440 controls; RR 0·99 [0·89–1·10]; p=0·84). For the incidence (hospitalisation 
or death) rates of speciﬁ c diseases, RRs were as follows: pulmonary embolus 1·87 (95% CI 1·13–3·07, p=0·01 [including 
0·2% mortality in both treatment groups]), stroke 1·06 (0·83–1·36), ischaemic heart disease 0·76 (0·60–0·95, p=0·02), 
and endometrial cancer 1·74 (1·30–2·34, p=0·0002). The cumulative risk of endometrial cancer during years 5–14 was 
3·1% (mortality 0·4%) for women allocated to continue versus 1·6% (mortality 0·2%) for controls (absolute mortality 
increase 0·2%). 
Interpretation For women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years 
produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with 
results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen 
treatment can approximately halve breast cancer mortality during the second decade after diagnosis.
Funding Cancer Research UK, UK Medical Research Council, AstraZeneca UK, US Army, EU-Biomed.
Introduction
For women with oestrogen receptor (ER)-positive breast 
cancer, treatment for 5 years with adjuvant tamoxifen 
substantially reduces the rate of recurrence not only 
during the treatment period but throughout the ﬁ rst 
decade, and reduces breast cancer mortality by about 
a third throughout the ﬁ rst 15 years (including 
years 10–14), with little net eﬀ ect on other mortality.1 
Although 5 years of tamoxifen is more eﬀ ective than is 
1–2 years of treat ment,1,2 whether 10 years of treatment 
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would have an even greater eﬀ ect on breast cancer 
recurrence and mortality in ER-positive disease is 
not known.3,4 Conversely, treatment with 5 years of 
tamoxifen can cause side-eﬀ ects such as endometrial 
cancer and thromboembolic disease,1,5 and continuing 
tamoxifen for an additional 5 years is likely to increase 
these side-eﬀ ects.
Early trials of continuing adjuvant tamoxifen to 10 years 
versus stopping tamoxifen at 5 years6–8 recruited relatively 
few patients. Although some of these studies had adverse 
early results,9 the small numbers of patients meant that 
these adverse results could have been due to the play of 
chance, so larger trials were needed.3,4,10
Moreover, as 5 years of tamoxifen has a prolonged 
carryover eﬀ ect after treatment ends, with a substantial 
reduction in mortality throughout the ﬁ rst 15 years, trials 
of continuing beyond 5 years of tamoxifen should 
eventually be followed up to beyond 15 years.4 The UK 
adjuvant Tamoxifen—To oﬀ er more? (aTTom) trial 
randomly allocated 7000 women, most with unknown ER 
status, to continue tamoxifen to 10 years or stop at 
5 years, but has yet to report long-term ﬁ ndings.11–13 We 
report results from the global Adjuvant Tamoxifen: 
Longer Against Shorter (ATLAS) trial, which randomly 
allocated 12 894 women to continue tamoxifen to 10 years 
or stop at 5 years. Our main analyses of breast cancer 
outcomes involve only the 6846 women with ER-positive 
disease (sensitivity analyses shown in the appendix 
include the other women); side-eﬀ ect analyses include all 
12 894 women, regardless of whether the ER status of 
their disease was positive, negative or unknown.
Methods
Study design and participants 
ATLAS is an international trial of continuation of adjuvant 
tamoxifen for an extra 5 years. Women were eligible for 
randomisation if they had had early breast cancer (in 
which all detected disease could be removed); they had 
subsequently received tamoxifen for some years and were 
still on it (or had stopped in the past year and could resume 
treatment with little interruption); they appeared clinically 
free of disease (with any local recurrence removed and no 
distant recurrence detected); follow-up seemed practicable; 
and substantial uncertainty was shared by the woman and 
her doctor as to whether to stop tamoxifen or continue for 
about 5 more years. No restrictions were placed on age, 
type of initial surgery or histology, hormone receptor 
status, nodal status, or other treatments.
Any contraindications to continuation of tamoxifen 
precluded entry; clinicians were responsible for assess-
ment of these contraindications, which were not protocol-
deﬁ ned. However, the protocol did suggest clinicians 
consider pregnancy, breastfeeding, retinopathy, need for 
coagulation therapy, endometrial hyperplasia, other 
serious toxicity attributed to tamoxifen, negligibly low risk 
of death from breast cancer, or presence of another life-
threatening disease as possible contraindications.
ATLAS recruited patients from 36 countries or regions 
during 1996–2005. In general, each country or region 
had a coordinator on the international steering com-
mittee who liaised with collaborators at local hospitals to 
help ensure eligible patients were considered and, if 
entered, treated and followed up appropriately. Ethical 
approval was provided by the Oxford Tropical Research 
Ethics Com mittee, national and regional ethics commit-
tees where applicable, and local ethics committees in 
each hospital. Patients were oﬀ ered information leaﬂ ets 
in local languages. After patients provided signed con-
sent, base line characteristics were recorded and patients 
were entered into the study by post, telephone, or fax to 
the Oxford Clinical Trial Service Unit (CTSU) or to four 
national or regional centres (listed at the end of the 
paper). Forms were stored in the CTSU, with copies at 
local hospitals.
When ATLAS began in 1996, 2 years and 5 years of 
tamoxifen were both standard treatment options,14 so 
patients were eligible irrespective of previous duration 
of tamoxifen treatment. Shortly afterwards, a consensus 
emerged that 5 years of treatment was better than 
2 years of treatment.2,10 Entry with less than 4 years of 
previous tamoxifen (and, in most countries, of women 
with ER-negative disease) was therefore stopped in 
2000, before ATLAS had meaningful results. The 
women who had entered ATLAS after less than 4 years 
of tamoxifen will be reported separately within an 
update of the Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) meta-analyses2 of longer treatment 
versus about 2 years of treatment (ﬁ gure 1). This report 
is of the remain ing women; as they had completed a 
15 244 women randomly allocated* 
7629 to continue tamoxifen for another 5 years  
7615 to stop tamoxifen immediately  
2350 excluded completely, as tamoxifen duration before random 
allocation was <4 years  
12 894 included in analyses of side-eﬀects, among whom  
median tamoxifen duration was 5 years (IQR 4·8–5·2)  
6454 allocated to continue tamoxifen to 10 years  
6440 allocated to stop tamoxifen at 5 years
6048 excluded from analyses of main eﬀects, as ER status was 
unknown or negative 
6846 with ER-positive disease included in analyses of main eﬀects on 
recurrence and breast cancer mortality   
3428 allocated to continue tamoxifen to 10 years  
3418 allocated to stop tamoxifen at 5 years   
Figure 1: Trial proﬁ le, showing the diﬀ erent populations analysed to assess 
the side-eﬀ ects and the main eﬀ ects of continuing tamoxifen to 10 years 
versus stopping tamoxifen at 5 years 
ER=oestrogen receptor. *39 patients were allocated twice in error, but stayed on 
their original allocation. Excludes 18 patients entered in error (17 with distant 
recurrence and one without ethics approval). 
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median of 5 (IQR 4·8–5·2) years of tamoxifen, each 
patient’s entry date counts as year 5 (ignoring exact 
prior durations).
Randomisation 
The CTSU or the four regional or national centres used 
CTSU software to allocate eligible women randomly to 
continue tamoxifen to 10 years (stopping only if a deﬁ -
nite contraindication emerged) or to stop tamoxifen 
immediately at 5 years (open control). No placebo treat-
ment was used among controls, and tamoxifen was 
restarted only if a deﬁ nite indication was thought to have 
emerged. Randomisation was minimised 1:1 to balance 
treatment allocation by country or region and by major 
prognostic factors (age group, node negativity, tumour 
diameter, and ER status).
Procedures
Other than duration of tamoxifen treatment, patient 
manage ment was at the responsible clinician’s discretion. 
The tamoxifen regimen before and during ATLAS was 
almost always Nolvadex 20 mg per day; where tamoxifen 
was not aﬀ ordable, free Nolvadex was provided by the 
study. Patients were not required to make any extra visits, 
and no extra investigations were required. Central organ-
isers sent forms to responsible clinicians every year 
asking about use of tamoxifen or other adjuvant endo-
crine treatments, breast cancer recurrence, new primary 
cancer incidence (particularly endometrial cancer), 
reasons for any hospital admissions (particularly hyster-
ectomy and myocardial infarction), and, if the patients 
had died, underlying cause of death (asking particularly 
about breast cancer, endometrial cancer and myocardial 
infarction); death certiﬁ cates were also sought. Recur-
rence was deﬁ ned as ﬁ rst recurrence after ATLAS entry of 
any breast cancer (new or same tumour, distant [including 
unspeciﬁ ed or multiple sites], loco regional, or contra-
lateral). Yearly follow-up forms might report only the 
worst new endpoint, so if no recurrence had been 
recorded before a death from breast cancer (or if only 
contralateral or locoregional recurrence had been 
recorded before a death), we assumed distant recurrence 
just preceded death. Deaths from unknown causes 
without any recorded recurrence were regarded as 
unrelated to breast cancer. Events were coded, generally 
in ignorance of (but not masked to) treatment allo-
cation, by the ATLAS principal investigator (CD) accord-
ing to the 10th International Classiﬁ cation of Diseases 
(ICD-10).15 Data errors were sought centrally by extensive 
manual or computer checks, and investigated.
Although 6846 (53%) of 12 894 women had ER-positive 
disease, 4800 (37%) had unknown ER status. A retro-
spective project sought missing ER values, but the project 
was soon abandoned (because sample retrieval and assays 
diﬀ ered between women still attending hospital for 
continued tamoxifen and those who had stopped 
treatment). The retrospective assay results from this 
project are not included in the main analyses, although 
the assays that were done supported reports16 that ER-
positivity is substantially less common in Asia than in 
Europe. (Many ER-untested samples were from Asia, 
suggesting that only about 60% of all ER-untested samples 
would, if tested, have been ER-positive; appendix p 26).
Until mid-2010, when the last trial treatment ended, 
yearly interim analyses (split by ER status) of recur rence, 
death with recurrence, and cause-speciﬁ c mortality 
before recurrence were sent to an independent data 
monitoring committee.
Any ER status ER-positive
Continue 
tamoxifen to 
10 years 
(n=6454)
Stop
tamoxifen 
at 5 years 
(n=6440)
Continue 
tamoxifen to 
10 years 
(n=3428)
Stop 
tamoxifen 
at 5 years 
(n=3418)
Status at diagnosis
ER status
ER-positive 3428 (53%) 3418 (53%) ·· ··
ER-negative 625 (10%) 623 (10%) ·· ··
ER-unknown 2401 (37%) 2399 (37%) ·· ··
Age, years 
<45 (median 40) 1246 (19%) 1236 (19%) 640 (19%) 630 (18%)
45–54 (median 49) 2070 (32%) 2076 (32%) 1090 (32%) 1099 (32%)
55–69 (median 61) 2557 (40%) 2567 (40%) 1373 (40%) 1357 (40%)
≥70 (median 73) 581 (9%) 561 (9%) 325 (9%) 332 (10%)
Nodal status
Node-negative 3360 (52%) 3354 (52%) 1832 (53%) 1845 (54%)
N1–3 1667 (26%) 1621 (25%) 938 (27%) 893 (26%)
N4 or more 968 (15%) 965 (15%) 536 (16%) 534 (16%)
Unknown 459 (7%) 500 (8%) 122 (4%) 146 (4%)
Tumour diameter
1–20 mm 2462 (38%) 2463 (38%) 1660 (48%) 1620 (47%)
21–50 mm 2749 (43%) 2727 (42%) 1309 (38%) 1328 (39%)
>50 mm 620 (10%) 628 (10%) 251 (7%) 252 (7%)
Unknown 623 (10%) 622 (10%) 208 (6%) 218 (6%)
Status at ATLAS trial entry
Year of entry
1995–99 1538 (24%) 1541 (24%) 521 (15%) 527 (15%)
2000–02 2755 (43%) 2752 (43%) 1415 (41%) 1403 (41%)
2003–05 2161 (33%) 2147 (33%) 1492 (44%) 1488 (44%)
Previous duration of tamoxifen, years
4–4·9 2149 (33%) 2129 (33%) 1095 (32%) 1081 (32%)
5–5·9 3690 (57%) 3702 (57%) 2103 (61%) 2105 (62%)
≥6 615 (10%) 609 (9%) 230 (7%) 232 (7%)
Local recurrence before entry
Yes (successfully managed) 128 (2%) 121 (2%) 38 (1%) 37 (1%)
No 6316 (98%) 6307 (98%) 3382 (99%) 3373 (99%)
Unknown 10 (<1%) 12 (<1%) 8 (<1%) 8 (<1%)
Ever any contralateral primary
Yes 151 (2%) 157 (2%) 75 (2%) 80 (2%)
No 6297 (98%) 6276 (97%) 3350 (98%) 3332 (97%)
Unknown 6 (<1%) 7 (<1%) 3 (<1%) 6 (<1%)
(Continues on next page)
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Statistical analysis
The protocol stated that 20 000 patients would need to be 
randomised in ATLAS and the other trials of tamoxifen 
duration to detect reliably an absolute diﬀ erence of 
2–3% in mortality. Entry to ATLAS was halted in 2005 
(with 12 894 patients, including 6846 with ER-positive 
disease) because the MA.17 trial17 showed beneﬁ t 
from continued endocrine treatment after 5 years of 
tamoxifen. We report the dataset of Aug 31, 2012, because 
in September, 2012 this dataset was supplied to help 
update the periodic EBCTCG metaanalyses of all 
tamoxifen duration trials,2 which will eventually become 
public. After this preliminary report, further follow-up 
of ATLAS will continue. 
Intention-to-treat log-rank analyses, using in-house 
programs, yield the event rate ratio (RR; also known as 
risk ratio) and its standard error, the CI, and the two-
sided p value.1,2,18 If a log-rank statistic (observed – expected 
[O – E]) from a main or sensitivity analysis has variance V, 
then RR = exp([O – E] / V). Kaplan-Meier graphs show 
absolute risks during years 5–14. Analyses (of the ﬁ rst 
relevant event since entry) were of: recurrence (censored 
at death from other causes), side-eﬀ ects (censored at 
recurrence), breast cancer mortality, and overall mortality. 
Breast cancer mortality analyses subtracted the log-rank 
statistics for death without recurrence from those for 
overall mortality1,2 (without assuming all recur rences are 
equally life-threatening).
We used data for all patients with ER-positive, ER-
negative, or ER-untested disease to assess side-eﬀ ects, 
but data for patients with ER-negative or ER-untested 
disease cannot contribute directly to assessment of 
eﬀ ects in ER-positive disease. Therefore, the main 
empha sis in this report is on non-breast-cancer outcomes 
in all 12 894 women, but on recurrence and breast cancer 
mortality only in the 6846 women with ER-positive 
disease (as in the recent EBCTCG meta-analyses of 
tamoxifen trials1).
In addition, sensitivity analyses (appendix pp 14–18) 
combine results in ER-positive and ER-untested disease 
(taking the eﬀ ect in ER-untested to be 60% of that in ER-
positive disease; appendix p 26) by adding 0·6 times the 
log-rank (O – E) statistic for ER-untested disease to that 
for ER-positive disease, changing the variance V accord-
ingly, then again using RR = exp([O – E] / V).
The protocol-deﬁ ned main analysis (appendix pp 27–49) 
was of all-cause mortality in all women, irrespective of 
ER status or previous tamoxifen duration; this analysis is 
provided. The questions that still need answering about 
tamoxifen duration have, however, changed since ATLAS 
began, and the main analyses in the present paper are in 
line with those changes. Negative ER measurements are 
known to identify reliably patients with little or nothing 
to gain from tamoxifen. Moreover, for patients with ER-
positive disease, 5 years of tamoxifen is known to be 
better than 2 years of tamoxifen (although the full 
beneﬁ ts take at least 15 years to emerge), and 5 years of 
Any ER status ER-positive
Continue 
tamoxifen to 
10 years 
(n=6454)
Stop
tamoxifen 
at 5 years 
(n=6440)
Continue 
tamoxifen to 
10 years 
(n=3428)
Stop 
tamoxifen 
at 5 years 
(n=3418)
(Continued from previous page)
Entire breast ever removed
Yes 4634 (72%) 4563 (71%) 2230 (65%) 2162 (63%)
No 1819 (28%) 1874 (29%) 1198 (35%) 1255 (37%)
Unknown 1 (<1%) 3 (<1%) 0 1 (<1%)
Hysterectomy
Yes 1066 (17%) 1160 (18%) 620 (18%) 679 (20%)
No 5359 (83%) 5254 (82%) 2792 (81%) 2728 (80%)
Unknown 29 (<1%) 26 (<1%) 16 (<1%) 11 (<1%)
Menopausal status
Premenopausal 537 (8%) 521 (8%) 326 (10%) 304 (9%)
Postmenopausal* 5778 (90%) 5784 (90%) 3035 (89%) 3044 (89%)
Perimenopausal or unknown 139 (2%) 135 (2%) 67 (2%) 70 (2%)
Geographical distribution
Europe, Australia, New Zealand, 
USA, and South Africa†
2515 (39%) 2529 (39%) 1595 (47%) 1599 (47%)
Latin America‡ 1759 (27%) 1771 (28%) 982 (29%) 971 (28%)
Asia and Middle East§ 2180 (34%) 2140 (33%) 851 (25%) 848 (25%)
ER=oestrogen receptor. ATLAS=Adjuvant Tamoxifen: Longer Against Shorter. *Artiﬁ cial or natural menopause. 
†Predominantly of European origin. ‡Argentina, Brazil, Chile, Colombia, Cuba, Mexico, and Paraguay. §India, China, 
other Asia or the Middle East.
Table 1: Characteristics of patients at diagnosis and at ATLAS trial entry (~5 years later)
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Figure 2: Treatment compliance (A) and proportion of patients in follow-up (B) by year since randomisation 
for 6846 women with ER-positive disease (54% node-negative)
*>99% tamoxifen. 
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tamoxifen has little net eﬀ ect o n mortality not caused by 
breast cancer (despite speciﬁ c side-eﬀ ects such as 
endometrial cancer).1,2
Therefore, the main issue is how, in ER-positive disease, 
10 years of treatment compares with 5 years of tamoxifen 
in terms of main eﬀ ects on recurrence and breast cancer 
mortality, and how the speciﬁ c side-eﬀ ects of 10 years and 
5 years of tamoxifen diﬀ er.1,2,10
If the aim is to assess eﬀ ects on breast cancer outcomes 
in ER-positive disease, analyses need to be based either on 
the ﬁ ndings in patients known to have ER-positive disease 
(which are straightforward to present and are provided in 
full) or on a combination of the ﬁ ndings in ER-positive 
and ER-untested disease (which are provided as sensitivity 
analyses). Emphasis on breast cancer outcomes only in 
ER-positive disease was proposed by the data monitoring 
committee statistician (RP) who knew the ATLAS results, 
but the results from the main and sensitivity analyses 
were much the same: appendix pp 14–18.
This study is registered, number ISRCTN19652633.
Role of the funding source
Oxford University (Oxford, UK) was the trial sponsor. The 
study was designed, conducted, analysed, interpreted and 
reported by the investigators independently of all funding 
bodies (who saw the manuscript only after acceptance). 
CD, HP, JG, RG, and RP had full access to all data and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
Figure 1 describes the diﬀ erent populations that were 
analysed to assess the side-eﬀ ects and the main eﬀ ects 
of continuing tamoxifen to 10 years versus stopping 
tamoxifen at 5 years. After exclusion of 18 women who 
had been entered in error and 2350 women who had 
completed a median of only 2·4 years (IQR 2·0–3·1) of 
adjuvant tamoxifen, 12 894 women remained who had 
completed a median of 5·0 years (4·8–5·2) of adjuvant 
tamoxifen. All were included in the analyses of side-
eﬀ ects, regardless of ER status. 
After exclusion of a further 6048 women with ER status 
unknown or with ER-negative disease, 6846 women 
with ER-positive disease remained for the main analy-
ses of the eﬀ ects on breast cancer recurrence and breast 
cancer mortality. Table 1 shows the characteristics of the 
included patients.
Figure 2 shows compliance with the trial treatment 
allocation. Among women who were without recurrence 
2 years after entry (ie, at year 7 after diagnosis), 84% of 
those allocated to continue were still on tamoxifen com-
pared with 4% of controls, a diﬀ erence of 80%. Fewer 
than 1% of women were receiving any adjuvant endocrine 
treatment other than tamoxifen.
Figure 2 also shows that the completeness of follow-up 
was similar in both treatment groups. In each group 91% 
of the survivors were still being followed up 10 years after 
diagnosis and 77% were still being followed up 15 years 
after diagnosis; these proportions will increase as more 
5–9 years: RR 0·90 (0·79–1·02)
≥10 years: RR 0·75 (0·62–0·90)
All years: log-rank p=0·002
5–9 years: RR 0·97 (0·79–1·18)
≥10 years: RR 0·71 (0·58–0·88)
All years: log-rank p=0·01
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Figure 3: Recurrence (A) and breast cancer mortality (B) by treatment allocation for 6846 women with ER-positive disease
Bars show SE. Recurrence rates are percentage per year (events/patient-years of follow-up). Death rates (overall rate – rate in women without recurrence) are 
percentage per year (SE). ATLAS=Adjuvant Tamoxifen: Longer Against Shorter.
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follow-up accumulates. Some incompleteness was due to 
a few centres withdrawing and stopping all follow-up in 
both treatment groups. Nine patients allocated to con-
tinue tamoxifen and ten controls withdrew consent to 
further follow-up, but their earlier follow-up is included. 
Log-rank analyses by allocated treatment, censored at the 
last available record, allow for any incompleteness of 
follow-up, yielding treatment comparisons with no 
material bias (especially as incompleteness did not diﬀ er 
between the two treatment groups).
We recorded 1328 recurrences (899 during years 5–9, 
379 during years 10–14, and 50 after reaching year 15). 
Among women with ER-positive disease, allocation to 
continue tamoxifen reduced the risk of recurrence 
(617 recurrences in 3428 women allocated to continue vs 
711 in 3418 controls; RR 0·84, 95% CI 0·76–0·94; 
p=0·002), reduced breast cancer mortality (331 deaths 
with recurrence in women allocated to continue vs 397 
in controls, p=0·01) and reduced overall mortality 
(639 deaths vs 722 deaths, p=0·01). The risk of recur-
rence during years 5–14 was 21·4% for women allocated 
to continue versus 25·1% for controls (absolute recur-
rence reduction 3·7%); ﬁ gure 3. There was no evidence 
of a rebound increase in the recurrence rate when 
tamoxifen treatment ended. Breast cancer mortality 
during years 5–14 was 12·2% for women allocated to 
Ratio of annual 
event rates (SE)
Events/women
Continue tamoxifen 
to 10 years
Stop tamoxifen 
at 5 years
Age at diagnosis (p=0·82)
<55 years
≥55 years
303/1730 (18%)
314/1698 (18%)
354/1729 (20%)
357/1689 (21%)
–29·6
–26·2
164·2
167·6
0·83 (0·07) 
0·86 (0·07)
Nodal status at diagnosis (p=0·82)
Node-negative
Node-positive/unknown
252/1832 (14%)
365/1596 (23%)
295/1845 (16%)
416/1573 (26%)
–22·0
–36·2
136·7
195·0
0·85 (0·08) 
0·83 (0·07)
Tumour diameter (p=0·99)
1–20 mm/unknown
>20 mm
298/1868 (16%)
319/1560 (20%)
338/1838 (18%)
373/1580 (24%)
–26·3
–29·0
158·9
172·9
0·85 (0·07) 
0·85 (0·07)
Previous duration of tamoxifen (p=0·43)
4–4·9 years
≥5 years
223/1095 (20%)
394/2333 (17%)
242/1081 (22%)
469/2337 (20%)
–12·7
–43·3
116·2
215·6
0·90 (0·09) 
0·82 (0·06)
Entire breast ever removed (p=0·61)
Yes
No/unknown
414/2230 (19%)
203/1198 (17%)
472/2162 (22%)
239/1256 (19%)
–42·2
–14·4
221·2
110·4
0·83 (0·06) 
0·88 (0·09)
Ever hysterectomised (p=0·99)
Yes
No/unknown
115/620 (19%)
502/2808 (18%)
143/679 (21%)
568/2739 (21%)
–10·8
–45·2
 64·4
 267·3
0·85 (0·11) 
0·84 (0·06)
Menopausal status at ATLAS entry (p=0·79)
Premenopausal
Postmenopausal or unknown
 64/326 (20%)
 553/3102 (18%)
   73/304 (24%)
638/3114 (20%)
 –7·2
 –48·8
 34·2
 297·6
0·81 (0·15) 
0·85 (0·05)
Geographic distribution (p=0·58)
European origin*
Asian/Middle Eastern origin
470/2577 (18%)
147/851 (17%)
552/2570 (21%)
159/848 (19%)
 –47·3
 –8·7
 255·4
 76·4
0·83 (0·06) 
0·89 (0·11)
Site of ﬁrst recurrence (p=0·24)
Isolated local
Isolated contralateral
Distant†
  79/3428 (2%)
109/3428 (3%)
429/3428 (13%)
106/3418 (3%)
141/3418 (4%)
464/3418 (14%)
–14·7
–18·0
–23·2
 46·2
 62·5
223·2
0·73 (0·13) 
0·75 (0·11)
0·90 (0·06)
Period of endpoint (years since diagnosis) (p=0·30)
0–4 (not applicable before ATLAS entry)
5–6
7–9
≥10
            Total
196/3428 (6%)
232/3110 (7%)
189/2605 (7%)
617/3428 (18%)
213/3418 (6%)
258/3073 (8%)
240/2526 (10%)
711/3418 (21%)
       ..
 –9·0
 –15·7
 –31·1
–55·9
        ..
 102·2
 122·5
 107·1
331·9
0·92 (0·09) 
0·88 (0·08)
0·75 (0·08)
10 years events
Log-rank
O–E
Variance
of O–E
Favours treatment
to 10 years
Favours stopping 
at 5 years
1·00·50 1·5 2·0
99% CI or            95% CI
Global heterogeneity p=0·8
0·845 (0·051)
p=0·002
Figure 4: Recurrence by treatment allocation for 6846 women with ER-positive disease, subdivided by patient or tumour characteristics and location or 
time of ﬁ rst recurrence
*Europe, Australia, New Zealand, USA, Latin America, and South Africa (all predominantly of European origin). †Including multiple and unspeciﬁ ed sites.
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Number of events Log-rank O – E Variance of O – E Event rate ratio (95% CI) p value*
Continue 
tamoxifen 
to 10 years 
Stop 
tamoxifen 
at 5 years
Mortality analyses, by ER status
ER-positive (3428 vs 3418)†
Any death 639 722 –47·7 340·2 0·87 (0·78–0·97) 0·01
Death with recurrence 331 397 –32·9 182·0 0·83 (0·72–0·96) 0·01
Death without recurrence 308 325 –14·8 158·1 0·91 (0·78–1·06) 0·24
ER unknown (2401 vs 2399)†
Any death 625 635 –10·5 314·6 0·97 (0·87–1·08) 0·55
Death with recurrence 302 334 –18·4 158·7 0·89 (0·76–1·04) 0·15
Death without recurrence 323 301 7·9 155·9 1·05 (0·90–1·23) 0·53
ER-negative (625 vs 623)†
Any death 123 116 3·5 59·7 1·06 (0·82–1·37) 0·66
Death with recurrence 63 63 0·0 31·5 1·00 (0·71–1·42) 0·99
Death without recurrence 60 53 3·4 28·2 1·13 (0·78–1·63) 0·52
Any ER status (6454 vs 6440)†
Any death 1387 1473 –54·7 714·5 0·93 (0·86–1·00) 0·04
Death with recurrence 696 794 –50·9 372·2 0·87 (0·79–0·97) 0·008
Death without recurrence‡ 691 679 –3·8 342·3 0·99 (0·89–1·10) 0·84
Analyses of events without prior recurrence‡, any ER status
Death without recurrence
Vascular death
Stroke 62 59 0·8 30·2 1·03 (0·72–1·46) 0·89
Pulmonary embolus 10 8 0·8 4·5 1·21 (0·48–3·04) 0·69
Heart disease§ 178 205 –16·1 95·7 0·85 (0·69–1·03) 0·10
Neoplastic death
Endometrial cancer¶ 17 11 2·8 7·0 1·49 (0·71–3·13) 0·29
Other neoplastic disease 78 75 0·4 38·2 1·01 (0·74–1·39) 0·94
Other death
Speciﬁ ed cause 171 161 2·3 82·9 1·03 (0·83–1·28) 0·80
Unspeciﬁ ed cause 175 160 5·1 83·7 1·06 (0·86–1·32) 0·58
Second cancer incidence 
Contralateral breast cancer 419 467 –28·9 221·5 0·88 (0·77–1·00) 0·05
Endometrial cancer¶ 116 63 24·8 44·8 1·74 (1·30–2·34) 0·0002
Primary liver cancer 3 3 –0·0 1·5 0·99 (0·20–4·90) 0·99
Colorectal cancer 46 52 –3·8 24·5 0·86 (0·58–1·27) 0·44
Unspeciﬁ ed site 254 251 –1·3 126·2 0·99 (0·83–1·18) 0·91
Non-neoplastic disease (ever hospitalised or died)
Stroke 130 119 3·8 62·2 1·06 (0·83–1·36) 0·63
Pulmonary embolus 41 21 9·7 15·5 1·87 (1·13–3·07) 0·01
Ischaemic heart disease 127 163 –20·2 72·5 0·76 (0·60–0·95) 0·02
Gallstones 75 66 3·7 35·2 1·11 (0·80–1·54) 0·54
Cataract 72 63 3·5 33·7 1·11 (0·79–1·56) 0·54
Bone fracture 62 70 –4·9 33·0 0·86 (0·61–1·21) 0·39
The log-rank analyses of death with recurrence are done by subtraction of the log-rank analyses of death without recurrence from those of any death. If O – E is negative, its 
value is about half the number of events prevented; if V is its variance, event rate ratio is exp([O – E] / V). ER=oestrogen receptor. *Two-sided. †In parentheses: number of 
women allocated to continue tamoxifen vs number allocated to control. ‡Delay of recurrence by continuation of tamoxifen increases woman-years at risk before recurrence 
by about 3% in ER-positive disease; the log-rank analyses allow for this, but crude comparisons of total numbers of events before recurrence do not. §Mainly heart disease, 
but includes all vascular causes apart from stroke and pulmonary embolus. ¶Mainly endometrial adenocarcinoma, but includes all other uterine tumours apart from cervical 
cancer; analyses of uterine tumour incidence exclude women with hysterectomy recorded at trial entry.
Table 2: Eﬀ ects of allocation (continue tamoxifen to 10 years vs stop at 5 years) on mortality with and without previous recurrence in each category of 
ER status at entry, and on various outcomes without previous recurrence in all women of any ER status 
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continue versus 15·0% for controls (absolute mortality 
reduction 2·8%).
The main eﬀ ects on recurrence and, particularly, on 
breast cancer mortality became apparent only during the 
second decade after diagnosis (ﬁ gure 3). For recurrence, 
the RR was less extreme during years 5–9 (0·90, 95% CI 
0·79–1·02; p=0·10) than after reaching year 10 (0·75, 
0·62–0·90; p=0·003), but the heterogeneity between the 
RRs in the two time periods was not signiﬁ cant (p=0·10). 
For breast cancer mortality the RR was again less extreme 
during years 5–9 (0·97, 0·79–1·18; p=0·74) than after 
reaching year 10 (0·71, 0·58–0·88; p=0·0016), and the 
heterogeneity between the mortality RRs in the two time 
periods was signiﬁ cant (p=0·04). 
To date, twice as many recurrences have been recorded 
during the ﬁ rst 5 years as during the second 5 years after 
randomisation, so taking all time periods together the 
overall recurrence RR in ER-positive disease is dominated 
by the ﬁ rst 5 years. Figure 4 shows various subgroup 
analyses for this overall result, with no signiﬁ cant 
heterogeneity of the proportional risk reduction with 
respect to patient or tumour characteristics or site of ﬁ rst 
recurrence. The reduction in distant recurrence is not 
separately signiﬁ cant in ﬁ gure 4 (p=0·12 for distant recur-
rence as ﬁ rst event, but p=0·05 for distant recur rence at 
any time; appendix p 20).
Table 2 subdivides by ER status the eﬀ ects of the 
treatment allocation on mortality with and without 
recurrence. For death with recurrence, the eﬀ ect of the 
treatment allocation in ER-unknown disease seems to 
be intermediate between the signiﬁ cant eﬀ ect already 
described in ER-positive disease and the lack of apparent 
eﬀ ect in ER-negative disease. 
Sensitivity analyses that use the intermediate treatment 
eﬀ ects in ER-unknown disease to help estimate the 
treatment eﬀ ects in ER-positive disease did not materially 
alter the estimated RRs for breast cancer outcomes in all 
time periods (appendix pp 14–18), but made the p values 
for them somewhat more extreme (recurrence p=0·0009, 
distant recurrence at any time p=0·02, breast cancer 
mortality p=0·004, and all-cause mortality p=0·011).
For death without recurrence in all 12 894 women, 
irrespective of ER status, there was no signiﬁ cant eﬀ ect of 
the treatment allocation, either overall or for death from 
any particular cause (table 2). In the hypothetical absence 
of any breast cancer mortality, the probability of dying 
from another cause during years 5–14 after breast cancer 
diagnosis would be 5% for women younger than 60 years 
at entry and 20% for older women.
Table 2 also describes various other events without 
previous recurrence in all women. For the incidence 
(hospitalisation or death) rates of speciﬁ c diseases, RRs 
were: pulmonary embolus 1·87 (95% CI 1·13–3·07, p=0·01 
[including 0·2% mortality in both treatment groups]), 
stroke 1·06 (0·83–1·36, p=0·63), ischaemic heart disease 
0·76 (0·60–0·95, p=0·02), and endometrial cancer 1·74 
(1·30–2·34, p=0·0002 [including all non-cervical uterine 
cancers]). The cumulative risk of endometrial cancer 
during years 5–14 was 3·1% (mortality 0·4%) for women 
allocated to continue tamoxifen versus 1·6% (mortality 
0·2%) for controls (absolute mortality increase 0·2%).
Discussion
Previous trials have shown that, for women with ER-
positive early breast cancer, 5 years of adjuvant tamoxifen 
substantially reduces recurrence rates throughout the 
ﬁ rst 10 years after diagnosis and substantially reduces 
breast cancer mortality throughout the ﬁ rst 15 years.1 
Thus, the eﬀ ects of 5 years of treatment with tamoxifen 
on annual rates of mortality persist for at least a decade 
after treatment ends. Because of this carryover beneﬁ t 
after only 5 years of tamoxifen, it was already recognised4 
when ATLAS began that there could well be little 
additional beneﬁ t during the ﬁ rst few years of additional 
treatment, even if worthwhile beneﬁ t would emerge later. 
With an average of 7·6 woman-years of further follow-up 
after entry at 5 years, the ﬁ ndings thus far available 
conform with these expectations. ATLAS has now shown 
that, compared with stopping after only 5 years of 
tamoxifen, continuing for another 5 years (to 10 years) 
provides further protection against recurrence and breast 
cancer mortality, particularly after reaching 10 years.
Table 2 includes the prespeciﬁ ed protocol analysis of 
overall mortality in all women in ATLAS irrespective of 
ER status, but this is less informative than are the main 
analyses in the present report of breast cancer outcomes 
in women with ER-positive disease. Inferences about the 
eﬀ ects of tamoxifen on recurrence and on breast cancer 
mortality in ER-positive disease can be made either from 
these main analyses or from the sensitivity analyses 
involving ER-untested disease (appendix pp 14–18), 
although these sensitivity analyses are somewhat depen-
dent on the assumed proportion that would have been 
ER-positive if tested. Irrespective of whether the main or 
the sensitivity analyses are preferred, the results are 
similar. Moreover, as follow-up was equally thorough in 
both treatment groups, ascertainment of mortality (parti-
cularly after treatment ends) is not materially biased by 
controls not having been given placebo tablets.
By combining results from the previous trials1 with the 
new results from ATLAS, we can estimate what would be 
seen in trials of 10 years of adjuvant tamoxifen compared 
with no treatment. Table 3 provides, by time since diag-
nosis, the recurrence RRs from the trials of 5 years of 
tamoxifen versus no tamoxifen and from the ATLAS trial 
of con tinuing tamoxifen to 10 years versus stopping at 
5 years, and multiplies these RRs together to estimate 
what would be seen in trials of 10 years of tamoxifen 
versus no tamoxifen. Table 3 also provides similar 
estimates for breast cancer mortality. The recurrence 
and, particularly, the mortality ﬁ ndings are remarkable, 
and suggest that in trials of 10 years of tamoxifen versus 
no tamoxifen, breast cancer mortality rates during the 
second decade after diagnosis would be almost halved, 
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although the real ﬁ nding is not the point estimate but the 
CI (which shows that the reduction could be as little as a 
third rather than a half).
However, both in trials of 5 years of tamoxifen1 and in 
ATLAS, there was a diﬀ erence of only about 80% between 
the prevalence of tamoxifen use in the two treatment 
groups, so the estimates in table 3 are likewise of what 
would be seen in trials of 10 years of tamoxifen compared 
with no tamoxifen that had only about 80% compliance. 
The risk reduction achievable by full compliance with 
10 years of tamoxifen should, therefore, be appreciably 
greater, strengthening the conclusion that breast cancer 
mortality during the second decade after diagnosis (or at 
least during years 10–14) can be approximately halved. 
Thus, good evidence now exists that 10 years of tamoxifen 
in ER-positive disease produces substantial reductions in 
rates of recurrence and in breast cancer mortality not 
only during the ﬁ rst decade (while treatment continues) 
but also during the second decade (after it ends).
Continued follow-up of ATLAS will eventually yield 
further evidence about eﬀ ects on breast cancer outcomes 
during the second decade after diagnosis. Before then, 
substantial additional information about events during 
the second decade will have been contributed by the other 
trials of continuing tamoxifen to 10 years versus stopping 
at 5 years (particularly aTTom, the UK counterpart of 
ATLAS, which reported little beneﬁ t during years 5–9 but 
has not yet reported on outcomes during the second 
decade13). EBCTCG meta-analyses of ATLAS, aTTom, and 
the smaller trials will eventually clarify the eﬀ ects on 
breast cancer outcomes 10–14 years after diagnosis (panel). 
Tamoxifen produces favourable lipid proﬁ le changes19–21 
and the ATLAS results do suggest some protection against 
ischaemic heart disease. Because, however, no signiﬁ cant 
protection against heart disease was seen in trials of 
tamoxifen versus no tamoxifen,1,2 the apparent reduction 
in ATLAS might be largely a chance ﬁ nding (especially 
since the apparent protection was against events after the 
treatment period, and long-term follow-up of trials of 
cholesterol-lowering statin treatment ﬁ nd little further 
beneﬁ t after treatment ends22). Conversely, although the 
US Food and Drug Administration lists stroke as a possible 
side-eﬀ ect,5,23 no apparent increase in stroke incidence or 
mortality was seen during the treatment period either in 
ATLAS or in the trials of 5 years of tamoxifen.1
However, deﬁ nite long-term side-eﬀ ects of tamoxifen 
do exist, which require longer follow-up and meta-
analyses of all relevant trials for ﬁ nal assessment. In both 
ATLAS and the trials of 5 years of tamoxifen versus no 
treatment,1,2 tamoxifen increases the incidence of endo-
metrial cancer in postmenopausal women who had not 
had a hysterectomy before trial entry. Although there is 
little risk in premenopausal women, life-table calcu-
lations for older women (together with allowance for the 
imperfect compliance with treatment allocations in 
trials) suggest that actual use of 5 years of adjuvant 
tamoxifen would produce an absolute 15 year endometrial 
cancer risk of about 2–3%,1 and that use of 10 years rather 
than 5 years of tamoxifen would produce an additional 
risk by year 15 of about 2%.
The death rate from endometrial cancer was, however, 
only about a tenth of the incidence rate, suggesting that 
full compliance with 10 years of tamoxifen in post-
menopausal women would produce a 15 year risk of a few 
per thousand of eventually dying from the excess of uterine 
cancer. This risk is greatly outweighed in ER-positive 
disease by the decrease in breast cancer mortality.
Panel: Research in context
Systematic review
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) periodically reviews trials 
of adjuvant tamoxifen versus no tamoxifen in early breast cancer and of longer versus 
shorter tamoxifen durations. The EBCTCG’s meta-analyses1,2 show that, in oestrogen 
receptor (ER)-positive disease, 5 years of adjuvant tamoxifen substantially decreases 
breast cancer recurrence, breast cancer mortality, and overall mortality (despite small 
absolute increases in endometrial cancer and pulmonary embolus). Previous trials have 
not, however, answered the question of how 10 years of tamoxifen compares with only 
5 years. Because the decrease in breast cancer mortality produced by 5 years of tamoxifen 
continues to be substantial for a decade after treatment ends (ie, throughout the ﬁ rst 
15 years after diagnosis), trials of 10 years versus 5 years of tamoxifen will need to be 
followed up for at least 15 years from diagnosis.
Interpretation
The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, with a mean of 7·6 years of 
further follow-up after entry at year 5, shows that recurrence and breast cancer mortality 
during the second decade after diagnosis are reduced more eﬀ ectively by 10 years of 
adjuvant tamoxifen than by 5 years. Although known side-eﬀ ects were increased (at least 
in postmenopausal women) by longer treatment, the absolute reduction in breast cancer 
mortality was an order of magnitude greater than the absolute increase in mortality due to 
these side-eﬀ ects. Taken together with the results from trials of 5 years of tamoxifen versus 
none, the results from ATLAS show that 10 years of eﬀ ective endocrine therapy can 
approximately halve breast cancer mortality during years 10–14 after diagnosis. Longer 
follow-up of ATLAS (and a meta-analysis of all such trials) will be needed to assess the full 
beneﬁ ts and hazards throughout the second decade.
A: eﬀ ects in meta-analyses 
of the trials of 5 years of 
tamoxifen vs none1 
(n=10 645)
B: eﬀ ects in the ATLAS trial 
of continuing tamoxifen to 
10 years vs stopping at 5 years 
(n=6846)
C: estimated eﬀ ects 
in a trial of 10 years 
of tamoxifen vs none 
(product of A and B)
Recurrence
0–4 years 0·53 (0·48–0·57)* 1 0·53 (0·48–0·57)*
5–9 years 0·68 (0·60–0·78)* 0·90 (0·79–1·02) 0·61 (0·51–0·73)*
≥10 years 0·94 (0·79–1·12) 0·75 (0·62–0·90)† 0·70 (0·54–0·91)†
Breast cancer mortality
0–4 years 0·71 (0·62–0·80)* 1 0·71 (0·62–0·80)*
5–9 years 0·66 (0·58–0·75)* 0·97 (0·79–1·18) 0·64 (0·50–0·82)‡
≥10 years 0·73 (0·62–0·86)‡ 0·71 (0·58–0·88)§ 0·52 (0·40–0·68)*
(A) Trials of 5 years of tamoxifen (n=10 645; ~80% complied). (B) ATLAS trial of 10 years vs 5 years of tamoxifen 
(n=6846; ~80% diﬀ erence in tamoxifen use [ﬁ gure 2]). (C) Hypothetical trial of 10 years of tamoxifen vs none (with 
~80% compliance). Two-sided p values in this table relate to particular time periods; values elsewhere combine all time 
periods. ER=oestrogen receptor. *p<0·00001. †p<0·01. ‡p=0·0001. §p=0·0016.
Table 3: Event rate ratios (95% CIs) in ER-positive disease, by time period from diagnosis 
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D H Depypere, E Everaert, F Geurs, J Kains, P Neven, D R Serreyn, 
R van den Broecke. Brazil [Victor H Medeiros Alencar, previously 
H M Salvador Silva], (Elivania d O Vieira), 1465—W Almeida Jr, 
O Alves Barbosa, S S Araujo, I Archangelo Jr, I Arruda, 
C Nogueira Barreira J Batista Lucena, G Bezerra Pinheiro, M Caleﬃ  , 
J T Campos Avelar, V d F Coutinho Maia Silva, E E Cronemberger, 
A B Diogenes, V R Emiliano, R d Freitas, A d Freitas Torres, R Farias, 
M D S C Freitas, M A A Funke, C Fuschino, 
D d Gama Dantes, C Gaspar, E Hoﬀ man, S F Juacaba, S H Lopes 
Marques, F Lorenzato, A Maroja, R Maroja, E Marques, M d O Matias, 
G P Medeiros, P H Melo, F A Miranda Henriques, M Monteiro, 
J W Mourao de Farias, J Moura, A P Mousinho, A M Murad, 
L Murillo Britto, A A Nonata d Andrade, P Pascoto, J Peixoto, 
G Peixoto Lima, M A Pereira, G d S Pinheiro, T Prado Wanderley, 
J H Reis, R A Ribeiro, V Ritter, R M Sales, M S Alencar, 
R Santiago Almeida, N Stenger, C Studart Leal, C Tosello de Oliveira, 
L L Vianna, S Zerbini, D Coelho d Sá, I A guiar Porto, G A d Moraes. 
Chile [Octavio Peralta, Bettina Müller, previously Rodrigo Arriagada] 1603—
E A Acevedo, J C Acevedo, R O Arevalo, R Baeza, A Belmar, M E Bravo, 
L Bronfman, J Camacho, M Campos, B Cardemil, P Carvajal, B Cerda, 
F Cisternas, E Contreras, J F Cornejo, A J Cubillos, C del Castillo, 
P Escobar, M Fernández, A Fica, M Fritis, G Gambi, O Giannini, 
L S Gomez, J Gutiérrez, C Hales, R Hasbún, P Huidobro, R Iglesis, 
O S Jury, H Krause, J M Lagos, A León, M León, J Madrid, C Mariani, 
R Martínez Lepe, R Martínez Rogers, L A Matamala, D Moreno, P Núñez, 
A Olcesse, P Olfos, L Orlandi, W Ortúzar, Y Pabst, H Paredes, E Pérez, 
J Pierart, V Pineda, A Pinto, Z Pizarro, G Rey, O Rivas, M Rodríguez, 
H Rojas, J Rosas, P Ruíz de Viñaspre, J M Russo, S San Martín, 
L Sepúlveda, J Solé, J Steinberg, M Toledo, C Torres, J M Torres, R Torres, 
S Torres, A Uribe, M Valenzuela, C Vásquez, I M Vigneaux, G Vigueras, 
A Vila, H Villagrán, M Villalón, V Zambrano, Z Zlatar, M Zúñiga. People’s 
Republic of China [Beijing: Yongfu Shao, Xiang Wang, Oxford: Yaochen 
Wang], 147—F Fan, Y P Gong, J L Huang, Z H Jin, W L Li, Z W Lin, 
H J Liu, P Liu, Q L Liu, X T Ma, D Pang, X M Qiao, K D Shi, Y Q Sun, 
L Wang, Y Z Wang, T Wu, Z B Xie, B Zhang, W Q Zhang, H P Zhao, 
W P Zhou, J B Zhu. Colombia [Claudia Ramirez, previously Carlos Castro], 
74. Croatia [Damir Vrbanec], 37: D Herceg, A Juretic, I Martinovic, 
V Paulinic-Diminic, D E Pezerovic, S Plestina. Cuba [Ramon d J Ropero, 
For tamoxifen, 10 years of treatment has greater pro-
tective eﬀ ects against ER-positive breast cancer than does 
5 years of treatment, so the same might well be true for 
any comparably eﬀ ective endocrine treatment, either 
with another selective oestrogen receptor modiﬁ er or, in 
postmenopausal women, with an aromatase inhibitor.24 
In both cases, 10 years of treatment should be expected to 
have a greater protective eﬀ ect than 5 years of treatment 
would have, although other endocrine treatments can, 
like tamoxifen, also have long-term side-eﬀ ects.
For premenopausal women with continued ovarian 
activity, however (among whom aromatase inhibitors are 
not an alternative to tamoxifen), there is little risk of 
tamoxifen causing uterine cancer or vascular side-eﬀ ects 
to counterbalance the large absolute reduction in breast 
cancer mortality. Hence, our results are particularly 
relevent to premenopausal women with ER-positive 
disease—and, young women protected by 10 years of 
tamoxifen from death from breast cancer gain several 
decades of life expectancy.
Contributors
CD, RG, RC, JG, MC, and RP designed the trial. AD, HP, JG, and YW 
(for China) did the data analyses. MA, VHA, RA, AB, XB, JB, SRD, JFF, 
PH, M-FH, MI, HK, JK, W-HK, BSM, IM, BM, AN, OP, FP, LP, TP, VR, 
MTR, ST, GU, and MV (alphabetic) coordinated more than 200 women 
per country or region. BR was the top randomiser; VHA, BSM, BR and 
RR followed up more than 400 women. CD, HP, JG, RG, RC, and RP 
performed statistical analyses, interpretation, and report writing. All 
authors approved the ﬁ nal report.
ATLAS coordinating centre and CTSU supporting staﬀ  (1995–2012)
Principal investigator: Christina Davies. Administrative oﬃ  ce: 
Jenny Sayer, Valerie Collett. Central randomisation: Jill Crowther, 
Angela Radley. Analysts/programmers: Antonella Delmestri, 
Jon Godwin, Yaochen Wang. Statisticians: Richard Gray, Hongchao Pan, 
Richard Peto. Former staﬀ : A Beighton, M Forster, A Headon, C Hope, 
S Knight, P McGale, S Mozley, H Monaghan, A Muldal, A Naughten, 
S Turner. CTSU also prepared the software that randomised in four 
regional or national coordinating centres (Australia/New Zealand: 
National Health & Medical Research Council Clinical Trials Unit; Italy: 
Consorzio Mario Negri Sud; Japan: Tokyo University Department of 
Epidemiology and Biostatistics, then from 2001 Japan Clinical Research 
Support Unit; Spain: Institut d’Investigació Biomèdica Sant Pau, 
Barcelona [FIS PI020391]). CONAC (Corporación Nacional del Cáncer: 
Director C Agosin) distributed Nolvadex in Chile. 
Data monitoring committee
Chair: R Souhami. Former chair: R Doll (deceased). Current members: 
D Altman, M Baum, R Collins, K I Pritchard, D Simpson. Former 
member: K Dickersin.
Steering committee
Co-chairs: R Arriagada, V Raina. Former chair: C Williams. International 
adviser: A Goldhirsch. Members: the national/regional coordinators (see 
below) and the Oxford Secretariat.
Collaborators 
Collaborators are listed by country or region (names in brackets show the 
past and present national or regional coordinators, and names in 
parentheses show current national or regional administrator. Numbers 
show number of patients entered with any previous tamoxifen duration). 
Argentina [Mirta Abraham, Reinaldo Chacón], (Fany Pernas), 893— 
H A Abud (deceased), C M Alasino, C A Algamiz, J A Alvarado Velloso 
(deceased), A M Alvarez, A Alvarez Gardiol, E Alvarez Gardiol, R Arca, 
H Arocena, L A Barbera, C Bas, A J Benitez Gil, M Brown Arnold, 
A O Bustos, L B Cedaro, E L Cigno, F A Colo, A Colombo Berra, 
F S Coppola (deceased), R Delia, M E Dominguez, M Fages, L E Fein, 
A N Genovese, N A Giacomi, I Gomez, E Gonzalez Vera, A Hannois, 
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previously Rolando Camacho], 110—R I Alvarez, R M Amador, 
M A Arbesu, L Ballesta, M Catala, A de la Torre, M Domecq, X Escobar, 
S Franco (deceased), M O’Farril, I Perez, A Reyes de la Paz, I Rodriguez, 
R Rodriguez, I Sanchez, J L Soriano, Z Valdes. Czech Republic 
[Lubos Petruzelka, Olga Pribylova (deceased)], 942—D Adamkova-Krakorova, 
M Ambrus, J Barkmanova, L Barsova, J Bartos, O Bednarik, V Benesova, 
M Brychta, M Brychtova, S Cahova, M Chodacka, J Chovanec, 
V Cmejlova, P Coupek, K Cwiertka, J Finek, M Hacklova, L Hanus, 
E Helmichova, M Holikova, J Holub, H Honova, K Hovorkova, 
P Hrabetova, P Hubnerova, L Hudinkova, D Justrova, H Kankova, 
P Karasek, M Kaspar, E Kindlova, I Kiss, I Kocak, M Kohoutek, 
I Kolarova, B Konopaisek, J T Kozak, R Kozevnikovova, L Kozisek, 
L Krasna, K Krizan, K Kubackova, M Kubecova, M Kuta, P Lemez, 
I Lorenz, L Loukotkova, S Lukesova, M Lysy, H Macharova, D Mackova, 
P Mares, S Martin, V Muller, R Neumanova, F Novy, L Ostrizkova, 
L Pavel Pavlov, S Pluhacek, J Prausova, J Pribylova, J Ruzickova, 
M Safanda, J Salvet, E Sedlackova, S Semonska, Z Seneklova, M Smakal, 
M Soumarova, S Spelda, V Spurny, W Strzondala, P Tesarova, 
V Tomancova, M Tomanova, K Trskova, H Vesela, K Vondrackova, 
J Vydra, R Vyzula, M Zemanova, M Zimovjanova, M Zvolsky. 
Egypt [Hussein Khaled], (A Badran), 465—S E Abd-Elmoneim Khalil, 
F Abu Taleb, A Badran, H El Akkad, A El-Khodary, R M Gaafar, 
N Gad El Mawla (deceased), A Hablas, K Ismail (deceased), M Moneer, 
M S Zaghloul. Estonia [Vaino Ratsep, Vahur Valvere], 12—A Kurvet, 
R Kutner, L Vahter. France [coordinated from Oxford Oﬃ  ce], 34—P Bernard, 
C Hill. Greece [Christos Alexopoulos, Evangelia Razis], 12. Hong Kong 
Special Administrative Region [Wing Hong Kwan], 549—G K H Au, 
P Chan, R T Chan, A Cheng, C Chi Kin, W Foo, H-C Cheng, C Kwok, 
DKwong, C Leung, W L Leung, R Liu King Yin, M Y Luk, R K Ngan, 
S K O, S W K Siu, J Suen, C C Tong, M Tong, S Y Tung, T K Yau, H Yiu. 
India [Vinod Raina, previously Indraneel Mittra], 3001—S H Advani, 
R A Badwe, B C Bakane, M N Bandyopadhyay, A Chandrasekharan, 
A Chaturvedi, A K D’Cruz, A C Deka, R Digumarti, M Dinesh, 
K A Dinshaw (deceased), J P Doshi, G Durgaprasad, R Gopal, V K Gupta, 
R Hawaldar, S Jain, K Jayakumar, S R Joharapurkar, S John, P K Julka, 
R Khanna, K C Kothari, M V Kumar, S Kumar, C Madhu, A Mathew, 
B S Mathew, B Mathor, A Mehta, F Mehta, G Mehta, N C Misra, S Misra, 
Y Nalini, H P Panchal, B Parekh, V Parmar, R Parshad, D D Patel, 
V Patel, S Premkumar, R Radhika, B Rajan, S K Sarkar, V Seenu, 
A Sengupta, P Shah, A Sharma, S C Sharma, K K Shenoy, H S Shukla, 
N K Shukla, S N Shukla, A Singh, K K Singh, A Srivastava, 
K Subrahmaniyam, P K Sur, H B Tongaonkar, R Vashisht, 
K V Veerendra Kumar, S Vijaya. Iran [Peiman Haddad], 247—K Dehshiri, 
F Amouzgar-Hashemi, H Madani, S H Mortazavi (deceased), 
M A Mousavizadeh, J Raafat, B Sadrolhefazi, M Tabatabaeefar. Ireland 
[T Finnegan], 1. Israel [Moshe Inbar, previously Noa Ben-Baruch, Adi Shani], 
253—F Barak, N Ben-Zui, R Catane, M Dinerman, E Evron, A Figer, 
M Gips, H Hayat, E Idelevich, R Isacson, V Kopp, F Kovner, L Marchasin, 
D Matcejevsky, L Olga, E Perepechi, I G Ron, T Safra, D Sarid, 
S Shlanger, E Shumeli, E Tepper, N Yaal-Hahoshen (deceased). Italy 
[Antonio Nicolucci], (Miriam Valentini), 292—G Amiconi, F Ascione, 
S Banducci, G Baratelli, F Battistelli, R Bianchi, S Bravi, A Chiara, 
B Dall’Omo, A De Matteis, F Di Costanzo, L Di Lullo, B di Nardo, 
S Ferrari, R Fiore, G Fornari, G Gini, M Giordano, M Giovannini, 
A Gravina, L Isa, L Laudadio, G Luchena, G Mantovani, M Marcellini, 
E Mari, P Marpicati, A Martoni, E Massa, A M Molino, A Nuzzo, 
R Pedersini, E Piana, N L Pinna, M C Pirozzoli, F Recchia, A Riccardi, 
F S Robbiati, E Rossi, M Sannicoló, G Ucci, M C Valli, C Zamagni. 
Japan [Yasuo Ohashi, Tadashi Ikeda, previously Yasuo Nomura], 
(Emi Yoshida) 137—S Akashi, K Aogi, E Arita, H Aoyama, A Emi, 
J Fujisawa, K Fujiwara, T Fukutomi, R Haruta, Y Hata, T Hayashida, 
T Hojo, Y Hozumi, H Inoue, K Ishida, M Ishida, C Kanbayashi, 
D Kanke, A Kataoka, A Kato, N Kato, N Katsumata, Y Kawabuchi, 
H Kawaguchi, M Kitajima, S Kobayashi, M Kodaira, C Koga, 
S Mitsuyama, M Miyauchi, E Mori, S Murakami, K Nagao, Y Nakamura, 
S Nishimura, R Nishimura, M Ohba, T Onishi, S Ohno, T Osako, 
S Osumi, M Sakata, M Sano, T Sato, Y Sato, H Shigematsu, H Takahashi, 
Y Takahashi, S Takashima, H Takenaka, K Tamae, K Tanaka, T Toge, 
M Toi, Y Uchida, N Uchiyama, H Yamaguchi, N Yamamoto, 
H Yamashita, T Yoshiyama. Latvia [Juris Berzins], 92—M Bitina, I Gailite, 
G Keire, T Purkalne, M Ratiani, Z Zvirbule. Lithuania [Konstantine 
Valuckas], 112—M Aizenas, D Andzeviciene, V Caropaite, A Cesas, 
A Ciceniene, E Juodzbaliene, J Kurtinaitis, A Luksyte, N Satkauskiene, 
G Smailyte, L Tamoshaitite, A Zlabiene. Mexico [Juan Zinser], 82— 
A Erazo Valle, E Maafs, M T Ramirez. Netherlands [Emiel Rutgers, Otilia 
Dalesio], (Lidwina Wever) 76—G Algie, J W Baars, J Belderbos, R Boom, 
J A C Brakenhoﬀ , O Dalesio, C A M de Swart, B de Valk, V Harskamp, 
O C Leeksma, K J Roozendaal, J Schrama, A K F Tanka, W E Terpstra, 
F Van Coevorden, D van Geldere, H Veen, S C Veltkamp, P Voogt. 
Oman [V Raina], 5—B A Bahrani. Paraguay [coordinated from Oxford], 
2—R Abed. Poland [Tadesuz Pienkowski, Maryna T Rubach], 
(J Kielanowska), 890—H Bassara, D Boguszewska, A Brandys, 
E Brewczynska, M Chudzik, K Czyzewska, I Debicka, 
T Dobielinska-Eliszews, E Filipczyk-Cisarz, M Foszczynska-Kloda, 
L Frackowiak, A Garncarek, J Giermek, E Glinka-Malasnicka, M Gornas, 
W Hajdukiewicz, P Hudziec, A Jagiello-Gruszfeld, M Jonca, 
B Karczmarek-Borowska, J Kielanowska, P Koralewski, B Koscianska, 
A Kucharska, P Kukawski, M M Kurianowicz, M Litwiniuk, 
M Marczak-Zietkiewicz, R Muchacki, J Oberc, K Pajak, A Pawlaczyk, 
J Perual, A Pienkowski, W Piskorski, M Pysz, M Rubach, R Rutkowski, 
M Sikorska, A Smietana, A Songin, M Stolarek, G Stopyra, 
M Suszko-Kazarnowicz, E Szybicka-Fliskowska, M Talerczyk, 
A Walaszkowska, K Warzocha, B Wawrzynczak, J Wegrzyn, 
B Wlonska-Kusy, J Wojtacki, K Zabkowska, A Zielezinska, B A Ziemba, 
D Zuziak, I Zygulski. Portugal [Helena Gervasio], 68—J E Albano, 
T Carvalho, P Madeira, I Pazos. Russia [Vladimir Semiglazov], 
320—N Barash, S Beljakov, A Bozhok, I Bulavina, O Burdaeva, 
S V Cheporev, M Cherenkova, V Chissov, L A Churilova, H Dmitrina, 
K Feodorov, T Fisanovich, v A Gorbounova, O Ivanova, L A Koroleva, 
S Kozhevnikov, A Lazarev, V Luppov, L Magcoeva, G Manikhas, 
D Melnikov, R Orlova, V Petrova, E Pogodina, V Predit, N Raevskaya, 
T Ricova, L Roman, I Seleznjeva, M V Shomova, S V Sidorov, J Spheglov, 
P Svetlouno, J Talovskiy, O M Vtoraya. Republic of South Africa 
[coordinated from Oxford, previously Elizabeth Murray, David Dent], 
84—N Bental, R Claus, C Cox, S Giles, A Gudgeon, A Hemus, E McEvoy, 
D H Mokone, D Moodley, S Mundawarara, G Paris, B Pokharel, 
B L Rapoport, P Ruﬀ , D Salton, E Sebastian, A Shelley, H Simonds, 
F Sitas, A Tarr, C Tarukandirwa, A L van Wijk, I D Werner. Spain 
[Xavier Bonﬁ ll], (Gerard Urrútia, Esther Canovas Martinez, Sera Tort), 
1730—M V Abrio, C Adansa, J Aguiar Morales, A Albero, J Alfaro, 
V Alija, D Almenar Cubells, C Alonso, A Alonso Amigo, 
G Alonso Curbera, E Alonso Redondo, I Alvarez, J Andrade Santiago, 
R Andrés, S Antolín Novoa, M I Antón, M A Arcusa Lanza, A Arrivi, 
A Avellà, J P Avellanal Barral, M A Badia i Canto, P Ballesteros Garcia, 
M d M Barros, R Bastús-Piulats, J N Batista López, E Batiste-Alentorn, 
J Belón Carrión, M Benavides, R Bernabé Caro, R Blanco Guerrero, 
U Bohn Sarmiento, M Boleda, C Bosch, J J Bretón Garcia, 
M A Burillo Cordero, J Buxó i Costa, E Calvo, L Calvo, F Capdevila, 
F J Carabantes, T Cardona Hernández, E Carrasco, J Casado, A Casas, 
S Catot Tort, J I Chacón López-Muñiz, M Chaves Conde, 
L Cirera i Noguera, E Ciruelos, R Colomer, J Cruz, M A De la Cruz, 
L De La Cruz, H De La Cueva, R Del Moral, M Domènech, 
F Dominguez Cunchillos, O Donay, J Dorta Delgado, A Duque Amusco, 
A Escobedo, P España Saz, E Espinosa Arranz, C Esteban Esteban, 
A Etxeberria, X Fabregat Mayol (deceased), C Falo, E Fernández Bautista, 
A Fernández Ortega, E Fonseca Sánchez, R M Franquesa Granell, 
E Gallardo, O Gallego, P Gallurt Moreira, M García, I García Carbonero, 
M J García López, M García Pérez, A Garrido Saldana, L Garrigós, M Gay, 
J R Germà Lluch, M Gil, U Giménez, A Gómez Bernal, B González, 
A González Del Alba, R González Del Val, L M González de Sande, 
R González Mancha, M M Gordon, C Gravalos Castro, I Guasch i Jordan, 
M Guillot, J Hornedo, L Iglesias Pérez, M D Isla, M A Izquierdo, 
E Jiménez Orozco, L Jolis López, I Juez, J M Laín, R Lasso de la Vega, 
M L Limón, M Llanos, P López, L J López Gómez, J J López López, 
A Lorenzo Penuel, A M Lozano Barriuso, R Llorente, H Manzano, 
J Martín Broto, B Martínez, P Martínez del Prado, G Martín García, 
C Mendiola, F Molina, C Molins, A Montano, J Montesinos, 
J A Moreno Nogueira, J Múñoz, M Múñoz, V Muñoz Madero, 
M T Murillo, M Nogué, M Noguer, B Ojeda, S Olmos, J Oramas, 
L Palomar, P Pastor, R Pérez Carrión, M A Pérez Escutia, J Pérez Olaguer, 
M d M Pérez Pérez, J Pérez-Regadera Gómez, C Pericay, 
J Petrement Briones, J M Piera Pibernat, A Plazaola, J Rifà, J A Rivero, 
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A Rodríguez, J M Rodríguez, R Rodríguez López, P Rodríguez Navarro, 
M Roget, M Ruiz Borrego, A Saenz, J Saﬁ z, E Saigí, M A Sala González, 
C Salas Buzón, J Saldana, M Salgado, V Sanahuja, A Sánchez Ruiz, 
J Sanz Lacalle, M Sanz Martín, J J Satrústegi, J Schneider, M A Seguí, 
S Servitja, M Sureda González, J Terrasa, A Tres Sánchez, I Tusquets, 
G Urrútia, V Valentín, M Valladares Ayerbes, S Vázquez, A Velasco, 
P Vicente, M J Villanueva, J Virizuela Echaburu, P Zamora Aunon. 
Taiwan, China [Ming-Feng Hou], 253—K M Chen, C-Y Chung, S-S Du, 
C-S Huang, V C Kok, S-J Kuo, C Lin, S-H Tu, Y-G Soong, J Y Zhang. 
Tunisia, 2—K Rahal. Turkey [Cemalletin Topuzlu], 55—I Aslay, D E Baltali, 
U Berberoglu, H Bolukbusi, E Buyukunal, S Camlibel, M Dincer, 
E U Erkocak, D E Ozdedeli, N Ozturk. UK (1 South African patient 
followed up in UK)—C De Souza, L D Harris. USA [coordinated from 
Oxford], 138—A J Afrookteh, W Allgaier, R Andrade, A Arevalos, 
K Armstrong, A Barnes, H Barnes, S G Barnes, S P Bazeley, R Blum, 
R Bowles, S Branton, M L Breslin, D S Bryant, D W Bryant, R Bullock, 
T Campana, R L Carter, R Chlebowski, J Choper, K Coady, T Coe, 
S Cohen, M Cotner, L Crocket, A Cruz, A Cutugno, S Davidson, 
A Dedona, S E El-Eid, E Eskander, A Estabrook, S Feldman, P Forth, 
S Francella, E Frankel, R B Fritchley, M Gillis, R Goldberg, G I Grad, 
S Gran, M Grossbard, L Hamilton, S Hasan, A Hassan, C Ho, L B Holt, 
J O Hopkins, J Infantolino, C M Jones, S Jones, M R Kinney, R A Kloss, 
P Kozuch, J Lalli, N La Marche, C Lepis, W Lerner, E Longenbach, 
M L Machuca, M Makhmetov, C Makowski, B Malliah, O McBeth, 
P Mencel, M Mesnard, A Messeih, T Mirzoyev, M Moraes, D Morrison, 
J Mueller, K Nahum, D Neville, B M O’Connor, M Ohler, R Orwoll, 
T Pagana, W Peck, T Peterson, J Pezzimenti, J Potter, D T Poulis, 
P G Rausch, G River, D K Roeder, B Schaeider, M Schreiber, N Shah, 
R B Shaw, A Smith, M E Stark, S Steelman, P Tartter, D Taylor, 
E Thompson, K Thompson, W Todhunter, A Topilow, G Unruh, C Uzel, 
B A White, R Willcoxon, D Williams, B Wood.
Conﬂ icts of interest
All authors declare that we have no conﬂ icts of interest. 
Acknowledgments
Our chief acknowledgment is to the women who participated in the 
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) study, the 
collaborating doctors, nurses, and data managers in many institutions in 
many countries (appendix pp 50–53), the international co-ordinating 
centre in the Oxford Clinical Trial Service Unit and Epidemiological Studies 
Unit (CTSU) and the CTSU randomisation service and infrastructure. 
IanJackson (deceased) greatly facilitated establishment of the study.
References
1 Early Breast Cancer Trialists Collaborative Group (EBCTCG). 
Relevance of breast cancer hormone receptors and other factors to 
the eﬃ  cacy of adjuvant tamoxifen: patient-level meta-analysis of 
randomised trials. Lancet 2011; 378: 771–84.
2 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). 
Eﬀ ects of chemotherapy and hormonal therapy for early breast 
cancer on recurrence and 15-year survival: an overview of the 
randomised trials. Lancet 2005; 365: 1687–717.
3 Swain SM. Tamoxifen: the long and short of it. J Natl Cancer Inst 
1996; 88: 1510–12.
4 Peto R. Five years of tamoxifen—or more? J Natl Cancer Inst 1996; 
88: 1791–93.
5 Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the 
prevention of breast cancer: current status of the National Surgical 
Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 
2005; 97: 1652–62.
6 Fisher B, Dignam J, Bryant J, et al. The worth of 5 versus more than 
5 years of tamoxifen therapy for breast cancer patients with negative 
nodes and estrogen-receptor positive tumors: an update of NSABP 
B-14. J Natl Cancer Inst 1996; 88: 1529–43.
7 Tormey DC, Gray R, Falkson HC, for the Eastern Co-operative 
Oncology Group. Postchemotherapy adjuvant tamoxifen therapy 
beyond ﬁ ve years in patients with lymph node-positive breast 
cancer. J Natl Cancer Inst 1996; 88: 1828–33.
8 Stewart HJ, Forrest AP, Everington D, et al. Randomised 
comparison of 5 years of adjuvant tamoxifen with continuous 
therapy for operable breast cancer. Br J Cancer 1996; 74: 297–99.
9 US National Institutes of Health. National Cancer Institute Clinical 
Announcement: adjuvant therapy of breast cancer—tamoxifen 
update. Bethesda, MD: National Institutes of Health, 1995.
10 US National Institutes of Health. NIH consensus statement. 
Adjuvant therapy for breast cancer: http://consensus.nih.gov/2000/
2000AdjuvantTherapyBreastCancer114html.htm (accessed Oct 10, 
2012).
11 Gray R, Davies C, Perry P. Tamoxifen for early breast cancer: better 
late than never. Ann Oncol 2000; 11: 505–07.
12 Earl H, Gray R, Kerr D, Lee M. The optimal duration of tamoxifen 
treatment for breast cancer remains uncertain: randomize into 
aTTom. Clin Oncol (R Coll Radiol) 1997; 9: 141–43.
13 Gray RG, Rea DW, Handley K, et al. ATTom: randomized trial of 
10 versus 5 years of adjuvant tamoxifen among 6,934 women 
with estrogen receptor-positive (ER+) or ER untested breast 
cancer—preliminary results. Proc Am J Clin Oncol 2008; 
26 (suppl 10): abstr 513. 
14 Davies C, McGale P, Peto R. Variation in use of adjuvant tamoxifen. 
Lancet 1998; 351: 1487–88.
15 WHO. International statistical classiﬁ cation of diseases and 
health-related problems, tenth revision. Geneva: World Health 
Organization, 1992.
16 Li CI, Kathleen E, Malone E, Daling JR. Diﬀ erences in breast cancer 
hormone receptor status and histology by race and ethnicity among 
women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 
2002; 11: 601–07.
17 Goss PE. Preventing relapse beyond 5 years: the MA.17 extended 
adjuvant trial. Semin Oncol 2006; 33 (suppl 7): S8–S12.
18 Early Breast Cancer Trialists’ Collaborative Group. Introduction and 
methods. In: Treatment of early breast cancer: worldwide evidence, 
1985–1990. Oxford: Oxford University Press, 1990. http://www.ctsu.
ox.ac.uk/research/meta-trials/ebctcg/original-methods-for-ebctcg-
meta-analyses (accessed Oct 10, 2012).
19 Love RR, Wiebe DA, Newcomb PA, et al. Eﬀ ects of tamoxifen on 
cardiovascular risk factors in post-menopausal women. 
Ann Intern Med 1991; 115: 860–64.
20 McDonald CC, Stewart HJ, for the Scottish Breast Cancer 
Committee. Fatal myocardial infarction in the Scottish Adjuvant 
Tamoxifen Trial. BMJ 1991; 303: 435–37.
21 Guetta V, Lush RM, Figg WD, et al. Eﬀ ects of the antioestrogen 
tamoxifen on low density lipoprotein concentrations and oxidation 
in post-menopausal women. Am J Cardiol 1995; 76: 1072–73.
22 Heart Protection Study Collaborative Group. Eﬀ ects on 11 year 
mortality and morbidity of lowering LDL cholesterol with 
simvastatin for about 5 years in 20,536 high-risk individuals. 
Lancet 2011; 378: 2013–20.
23 US Food and Drug Administration. Nolvadex (tamoxifen citrate). 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm154510.htm (accessed 
Oct 10, 2012).
24 Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer 
outcomes in adjuvant trials of aromatase inhibitors versus 
tamoxifen. J Clin Oncol 2010; 28: 509–18.
